Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Agora Inc (API) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Agora Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.55 (market cap $5.06B), while Agora Inc trades at $4.69 (market cap $385.97M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 13.1× Agora Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Agora Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | API | |
|---|---|---|
Market Cap | $5.06B | $385.97M |
Sector | Health | Technology |
52-Week High | $29.39 | $5.26 |
52-Week Low | $20.06 | $3.24 |
Enterprise Value | $4.18B | $138.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.21, up 2.67% today, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat expectations with EPS of $0.18 versus $0.07 expected, driven by robust Daybue and Nuplazid sales, leading to a raised 2026 revenue outlook. The stock shows high profitability with a net margin of 33.42% and ROE of 35.74%, though valuation metrics like EV/EBITDA of 42.2 indicate premium pricing.
The outlook is positive with 70% analyst buy ratings and a $33 consensus target, but risks include reliance on key drugs and Phase 2 trial results for remlifanserin due by October 2026. Cash flow volatility from heavy investing outlays in 2025 warrants monitoring, but operational strength supports growth potential.
Agora, Inc. (API) trades at $4.46, up 7.47% today, with a bullish technical signal driven by moving averages. The company reported Q1 2026 EPS of $0.01, beating expectations, and shows improving fundamentals with 2025 revenue of $141.06M and net income of $9.53M. Recent news highlights its Q2 2026 earnings report scheduled for August 13, 2026.
Outlook is positive with analyst consensus at 60% buy, supported by a low P/B of 0.68 and strong cash flow growth. Risks include high P/E of 50.68 and competitive pressures in AI technology. The stock offers value potential if earnings growth continues, but volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Agora Inc
Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.
Read more on API →
